ConductScience.org, home

Paper39620331

Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial.

Manchi RK and 2 others. Curr Diabetes Rev, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial. Papers, record 39620331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39620331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial.
PubMed
Journal
Curr Diabetes Rev
PubMed
Year
2025
PubMed
Publication types
Journal Article, Clinical Trial
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-06-05
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Manchi RKRajesh Kumarhttps://orcid.org/0000-0002-1377-7236
2Chenchula SSantenna
3Haritha MManchi

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Sulfonylurea CompoundsMajor topic
MetforminMajor topic
Hypoglycemic AgentsMajor topic
ThiazolidinesMajor topic
PyrazolesMajor topic
Dipeptidyl-Peptidase IV InhibitorsMajor topic
Humans
Male
Female
Drug Therapy, Combination
Middle Aged
Blood Glucose
Glycated Hemoglobin
Treatment Outcome
Aged
Adult
Insulin Resistance
Glycemic Control

Source PubMed

Download CSV of topics

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138524769Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused.Health Sci Rep2024https://conductscience.org/library/papers/38524769PubMed
28039601Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes.Diabetes1994https://conductscience.org/library/papers/8039601PubMed
325557969Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes.J Pediatr2015https://conductscience.org/library/papers/25557969PubMed
422974359Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.Curr Diabetes Rev2013https://conductscience.org/library/papers/22974359PubMed
535898461Incidence, Morbidity and years Lived With Disability due to Type 2 Diabetes Mellitus in 204 Countries and Territories: Trends From 1990 to 2019.Front Endocrinol (Lausanne)2022https://conductscience.org/library/papers/35898461PubMed
634708726Epidemiology of type 2 diabetes in India.Indian J Ophthalmol2021https://conductscience.org/library/papers/34708726PubMed
73186275613. Children and Adolescents: Standards of Medical Care in Diabetes-2020.Diabetes Care2020https://conductscience.org/library/papers/31862756PubMed
8349648319. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.Diabetes Care2022https://conductscience.org/library/papers/34964831PubMed
930291106Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care2018https://conductscience.org/library/papers/30291106PubMed
1027330726Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38).J Diabetes Investig2016https://conductscience.org/library/papers/27330726PubMed
1134514991
Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies.
Curr Diabetes Rev2022https://conductscience.org/library/papers/34514991PubMed
1217392540Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study.Diabetes Care2007https://conductscience.org/library/papers/17392540PubMed
1325295236Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis.CMAJ Open2014https://conductscience.org/library/papers/25295236PubMed
1430121726Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis.Diabetes Ther2018https://conductscience.org/library/papers/30121726PubMed
1522776014Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.Diabetes Obes Metab2012https://conductscience.org/library/papers/22776014PubMed
1631548957Effect of metformin on insulin levels, blood sugar, and body mass index in polycystic ovarian syndrome cases.J Family Med Prim Care2019https://conductscience.org/library/papers/31548957PubMed
1716599037Role of metformin in correcting hyperinsulinemia, menstrual irregularity and anovulation in polycystic ovary syndrome.J Ayub Med Coll Abbottabad2005https://conductscience.org/library/papers/16599037PubMed
1828484968A Practical Review of C-Peptide Testing in Diabetes.Diabetes Ther2017https://conductscience.org/library/papers/28484968PubMed
1930591792Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals.Saudi J Biol Sci2018https://conductscience.org/library/papers/30591792PubMed
2021537412Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients.Diabetes Metab J2011https://conductscience.org/library/papers/21537412PubMed

See all 43 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39620331

GET https://conductscience.org/api/papers/v1/39620331/references?page=2